期刊文献+

腹腔镜全结肠切除术联合放疗治疗Gardner综合征1例 被引量:1

Laparoscopic Total Colectomy with Radiation Therapy Gardner's Syndrome:one case report
下载PDF
导出
摘要 Gardner综合征是家族性结肠息肉病中一种较罕见的亚型,主要表现为结直肠多发息肉并伴有肠外病变,如硬纤维瘤、骨瘤等,目前外科手术是Gardner综合征治疗的首要选择,但腹腔硬纤维瘤的术后复发率极高,最终无法切除,导致患者死亡,被认为是Gardner综合征最难处理的症状,本病例通过腹腔镜手术及放疗的联合应用使得这一难题得到了很好的解决。 Gardner's syndrome is a variant of familinal adenomatous polypsis which leads to numerous external and internal symptoms .Such as desmoid and osteoma .Surgery is the most effective method of management for Gardner's syndrome . However ,patients suffer from desmoid tumors are challenging to treat due to its high recurrence rate .In this case a large desmoid was good local control treated by surgery and radiotherapy .
作者 房力男 王权
出处 《医学与哲学(B)》 2015年第4期64-65,共2页 Medicine & Philosophy(B)
关键词 腹腔镜全结肠切除 GARDNER综合征 放疗 laparoscopic total colectomy Gardner's syndrome radiation therapy
  • 相关文献

参考文献8

  • 1Gardner E J, Stephens F E. Cancer of the lower digestive tract in one family group[J]. Am J Hum Genet,1950,2(1) :41-48.
  • 2Jonathan B,Claire H, Mary T. Gardner syndrome-Review and report of a case[J]. Oral Oncoi Extra,2005,41 (5) :8,9-92.
  • 3Juhn E, Khachemoune A. Gardner syndrome: skin manifestations, differential diagnosis and management [J]. Am J Clin Dermatol. 2010,11(2):117-122.
  • 4Pinheiro I. V,Fagundes J J,Coy C S,et al. Multiple desmoid tumors in a patient with Gardner's syndrome: Report of a case[J]. Interna- tional Journal of Surgery Case Reports, 2014, 5 ( 7 ) : 370- 374.
  • 5Turina M, Pavlik C M, Heinimann K, et al. Recurrent desmoids deter mine outcome in patients with Gardner syndrome: a cohort study of three generations of an APC mutation-positive family across 30 years [J]. Int J Colorectal FAs.2013.28(6):865-872.
  • 6徐晓东,于恩达,刘连杰,傅传刚,张卫,孟荣贵.家族性腺瘤性息肉病伴发硬纤维瘤的诊治探讨[J].中华普通外科杂志,2010,25(7):596-598. 被引量:2
  • 7李岩,冯婷婷,凌孙彬,张馨丹,徐飞.肿瘤防治的自然观与适度治疗[J].医学与哲学(B),2013,34(11):20-22. 被引量:11
  • 8韩正祥,杜秀平.恶性肿瘤的诊疗思维策略[J].医学与哲学(B),2013,34(1):70-72. 被引量:6

二级参考文献33

  • 1项红军,王德盛.关于外科过度医疗的初步研究[J].医学与哲学,2005,26(3):16-17. 被引量:5
  • 2杨玲,李连弟,陈育德,D.M.Parkin.中国2000年及2005年恶性肿瘤发病死亡的估计与预测[J].中国卫生统计,2005,22(4):218-221. 被引量:336
  • 3Groen EJ,Roos A,Muntinghe FL,et al.Extra-intestinal manifestations of familial adenomatous polyposis.Ann Surg Oncol,2008,15:2439-2450.
  • 4Latchford AR,Sturt NJH,Neale K,et al.A 10-year review of surgery for desmoid disease associated with familial denomatous polyposis.Br J Surg,2006,93:1258-1264.
  • 5Fallen T,Wilson M,Morlan B,et al.Desmoid tumors-a characterization of patients seen at Mayo Clinic 1976-1999.Familial Cancer,2006,5:191-194.
  • 6Lefevre JH,Parc Y,Kemeis S,et al.Risk factors for development of desmoid tumours in familial adenomatous polyposis.Br J Surg,2008,95:1136-1139.
  • 7Iwama T,Kuwabara K,Ushiama M,et al.Identification of somatic APC mutations in recurrent desmoid tumors in a patient with familial adenomatous polyposis to determine actual recurrence of the original tumor or de novo occurrence.Familial Cancer,2009,8:51-54.
  • 8Sturt NJH,Clark SK.Current ideas in desmoid tumours.Familial Cancer,2006,5:275-285.
  • 9Soon JL,Lau WK,Seow-Choen F,et al.Unresectable desmoid tumours causing obstructive uropothy in familial adenomatous polyposis.Asian J Surg,2005,28:233-237.
  • 10Azizi L,Balu M,Belkacem A,et al.MRI features of mesenteric desmoid tumors in familial adenomatous polyposis.Am J Roentgenol,2005,184:1128-1135.

共引文献16

同被引文献12

  • 1ZHANG X, XU J, LIU H, et al. Predictive biomarkers for the efficacy of cetuximab combiaed with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective muhicenter phase 2 trial[J]. Med Oncoh2014,31(10) :226.
  • 2HAN K,JIN J,MAIA M,et al. Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase Ill trial [J]. AAPS J, 2014,16 (5) : 1056 -- 1063.
  • 3HU S, CA0 B, ZHANG M, et al. Epigenetic silencing BCL6B in duced colorectal cancer proliferation and metastasis by inhibiting P53 signaling[J].AmJ Cancer Res,2015,5(2):651- 662.
  • 4ROH K B,KIM I H,KIM Y S,et al. Synephrine inhibits eotaxin-1 expression via the STAT6 signaling pathway[J]. Molecules, 2014, 19(8) =11883--11895.
  • 5ADAR T,SHTE1NGART S,BEN YA'ACOV A,et al. From airway inflammation to inflammatory bowel disease= eotaxin-1, a key regu- lator of intestinal inflammation[J]. Clin Immunol, 2014,153 (1) : 199-208.
  • 6LOUPAKIS F,CREMOLINI C, MASI G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic eolorectal cancer[J]. N Engl J Med,2014,371(lT) :1609--1618.
  • 7PLANUTIS A K, HOLCOMBE R F,PLANOUTENE M V, et al. SW480 coloreetal cancer cells that naturally express Lgr5 are more sensitive to the most common chemotherapeutic agents than LgrS-negative SW480 cells [J]. Anticancer Drugs,2015,26(9) :942 -917.
  • 8ZENG H,ZHENG R,GUO Y,et al. Cancer survival in China,2003--2005:a population-based study[J]. Int J Caneer,2015,136(8)1921 1930.
  • 9ZHU F, LIU P, LI J, et al. Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3 ERK pathway and upregulation o{ MMP-3 expression[J]. ()ncol Rep,2014,31(5) :2049--2054.
  • 10KO U, CETINKAYA E, BOSTANCI E B, et al. Diagnostic signifi cance of serum eotaxin 1 level in gastric cancer patients[J]. Dis Markers,2013,35(5) :363--367.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部